Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Annals of Oncology

Topics

Medicine

Cancer Oncology

Internal Medicine

Surgery

Pulmonary And Respiratory Medicine

Show all topics

DOI

10.1016/j.annonc.2020.08.2098

License

CC-BY-NC-ND

Other Formats

PDF